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Context. Breakthrough cancer pain (BTcP) is widely recognized as a clinically
significant complication of chronic cancer pain. With most BTcP episodes peaking
in intensity within a few minutes and lasting for approximately 30 minutes, speed
of onset is crucial for effective pain management. Although the last decade has
seen the development of a number of rapid-onset fentanyl preparations, BTcP is
still typically managed by supplemental or rescue doses of the patient’s around-
the-clock medication, such as oral morphine. Importantly, although the fentanyl
preparations, such as fentanyl buccal tablet (FBT), sublingual fentanyl citrate
orally disintegrating tablet (ODT), and oral transmucosal fentanyl citrate lozenge
(OTFC), have all been proven to be efficacious in clinical studies, oral morphine
has never been specifically tested in BTcP, other than as a comparator in studies of
OTFC and fentanyl pectin nasal spray.
Objectives. To determine the relative contributions to pain relief from oral
morphine and the fentanyl preparations using placebo as a common comparator.
Methods. Relevant studies were identified by review of the literature and used in
a mixed-treatment meta-analysis to indirectly compare fentanyl preparations,
morphine, and placebo for the treatment of BTcP.
Results. Analysis incorporating the five relevant studies identified revealed that
although the fentanyl preparations provide superior pain relief vs. placebo in the
first 30 minutes after dosing (FBT provided an 83% probability of superior pain
relief, ODT 66%, and OTFC 73% vs. placebo), oral morphine performed little
better than placebo (56% probability).
Conclusion. This mixed-treatment analysis suggests that FBT, ODT, and OTFC
might provide more efficacious treatment options than oral morphine for
BTcP. J Pain Symptom Manage 2013;46:573e580.  2013 U.S. Cancer Pain Relief
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Introduction
For many years, opioids have remained the
mainstay of treatment for moderate-to-severe
cancer pain.1,2 Chronic pain is usually treated
with a fixed schedule, around-the-clock (ATC)
regimen, and by adhering to published guide-
lines, pain can be controlled in 80e90% of
patients with cancer.3 However, despite well-
controlled chronic pain, cancer patients may
experience breakthrough cancer pain (BTcP),
which has been defined as ‘‘a transient exacer-
bation of pain that occurs either spontane-
ously, or in relation to a specific predictable
or unpredictable trigger, despite relatively sta-
ble and adequately controlled background
pain.4’’ The reported prevalence of BTcP varies
widely, from 19% to 95%, depending on the
setting, survey methodology, and patients’ dif-
ferent perceptions and descriptions.5e7 BTcP
can occur during all stages of cancer, but it
seems to be more frequently experienced by
patients with advanced disease.8
Despite the significance of BTcP, data from
surveys suggest that it is far from optimally
treated,9e11 with many patients not receiving
appropriate additional analgesic medication
to treat their BTcP. Unsurprisingly, poorly
treated BTcP can reduce a patient’s quality of
life,11e13 and they also may have increased
levels of anxiety and depression, increased per-
ception of pain severity, and be dissatisfied
with their overall pain management.8 Inade-
quately relieved BTcP also represents a signifi-
cant economic burden, with affected patients
estimated to incur total medical costs five-
fold higher than patients without BTcP.14,15
BTcP has traditionally been managed with
oral opioids, also known as rescue medication,
given in addition to regularly scheduled ATC
analgesics.16 Although not specifically licensed
for the management of BTcP, oral, normal-
release formulations of morphine are the
most widely used, with other oral opioids,
such as oxycodone and hydromorphone,
sometimes prescribed.17 The major limitation
of this approach is that the onset of action of
these drugs may not match the temporalcharacteristics of many BTcP episodes. A
typical BTcP episode arises in a few minutes
and lasts for approximately 30 minutes,18,20
whereas observational studies have shown that
the onset of action of normal-release oral opi-
oids may be approximately 30 minutes, with
a mean time to peak effect of approximately
one hour.21
More recently, formulations of fentanyl, de-
livered via the oral transmucosal route, have
been developed and licensed specifically for
the management of BTcP. Commercially avail-
able oral transmucosal fentanyl products ap-
proved in the U.K. and Ireland for BTcP
include fentanyl buccal tablet (FBT, Effen-
tora; Cephalon UK, Ltd./Teva UK, Ltd., Har-
low, UK); sublingual fentanyl citrate orally
disintegrating tablet (ODT, Abstral; ProStra-
kan Group plc, Galashiels, UK); and oral trans-
mucosal fentanyl citrate lozenge (OTFC,
Actiq; Flynn Pharma, Ltd., Dublin, Ireland).
Clinical studies22e25 have shown that fentanyl
formulations have an onset of action of 15
minutes or less. Most of these studies were pla-
cebo controlled,22e25 although OTFC has
been compared with oral morphine.26 We
wanted to determine the relative contributions
to pain relief from morphine and oral fentanyl
preparations in comparison with placebo.Methods
We searched for randomized trials that eval-
uated FBT, ODT, and OTFC with either plac-
ebo or oral morphine in the management of
opioid-tolerant adult cancer patients with
BTcP. The search was undertaken in PubMed
from 1980 to October 2011 using the following
search terms: ‘‘breakthrough cancer pain,’’ ‘‘in-
cident pain,’’ ‘‘pain flare,’’ ‘‘morphine,’’ and
‘‘fentanyl,’’ limited by English language, and
randomized, controlled human clinical trials.
The search was supplemented by manual
searching of bibliographies of short-listed arti-
cles. Cephalon UK, Ltd. provided copies of
available clinical study reports for FBT and
OTFC.
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indirectly compare the fentanyl preparations,
morphine, and placebo for BTcP. This method-
ological approach has been previously used to
compare the fentanyl preparations against
each other;27 in this article, we report an analy-
sis comparing these preparations and mor-
phine with placebo. The overall likelihood
(probability) of superior pain relief, as mea-
sured by differences in pain intensity difference
(PID) scores, compared with placebo was calcu-
lated for the 15- to 60-minute interval post-
dosing, and split from 15 to 30 minutes and
45 to 60 minutes. In support of these probabil-
ity estimates, which are based on the sampling
distribution of efficacy comparisons, outcomes
also were expressed as a mean difference in
PID between treatments with 95% credible
levels (CRLs). A 95% CRL can be interpreted
as the range of values that includes 95% of
the probability distribution of the mean. For in-
terpretation purposes, and although derived
differently, the 95% CRL may be considered
analogous to a 95% confidence interval used
in traditional, frequentist analyses.
A fixed-effect model with normal prior and
posterior distributionswasused,withall analyses
performed in WinBUGS (Bayesian inference
Using Gibbs Sampling, The BUGS Project,
Medical Research Council Biostatistics Unit,
Cambridge, UK) 1.4.3 statistical software.27e29Results
Included Studies
We identified five studies in total (Table 1).
Four studies were placebo controlled: two vs.
FBT,22,23 and one each vs. ODT24 and OTFC;25
and one study compared OTFC and morphine
sulfate immediate-release (MSIR) drugs.26 We
extracted data for the meta-analysis from all
five studies relating to PID from baseline at dif-
ferent timepointspost-dosing (Table 2).27There
wasnoevidenceofgrossheterogeneity across the
study populations.
Mixed-Treatment Meta-Analysis
Likelihood of Superiority. When the oral opioids
were compared with placebo in the mixed-
treatment comparison, there was a 61% pro-
bability that MSIR would produce a better
outcome than placebo during the first 60minutes after dosing (a 50% probability repre-
sents equivalent efficacy; 67%, a 2:1 likelihood
of superior efficacy; 75%, a 3:1 likelihood;
99%, a 99:1 likelihood; and so on; Table 3).
The corresponding results for the fentanyl
preparations compared with placebo over 60
minutes were: FBT 97%, ODT 72%, and
OTFC 81%. The likelihood of superiority of
the fentanyl preparations over MSIR during
the first 60 minutes after dosing were FBT
68%, ODT 57%, and OTFC 66%.
For the first 30 minutes after dosing, the
likelihood of superiority over placebo was
56% for MSIR. Superiority estimates over pla-
cebo for the fentanyl preparations were 83%
for FBT, 66% for ODT, and 73% for OTFC
(Table 3). A similar pattern was observed for
the 45e60 minutes post-dosing interval, with
superiority over placebo marginally increased
for all of the opioids (#10% increase in likeli-
hood). When the fentanyl preparations were
compared with MSIR over the first 30 minutes
post-dosing, the likelihood of superiority esti-
mates were 58% for FBT, 56% for ODT, and
62% for OTFC. The likelihood of superiority
over MSIR was similar for the 45e60 minute
interval post-dosing (ODT 2% drop and
OTFC unchanged), apart from an 8% rise in
probability for FBT (to 66%).
Pain Intensity Differences. The mean PIDs were
consistently better for all of the opioids than
placebo at all recorded time points (Table 3).
However, the differences observed with the
fentanyl preparations were consistently around
double those observed with MSIR. Across the
first 60 minutes after dosing, the mean PID
(95% CRL) vs. placebo was 0.44 (2.07,
2.95) for MSIR compared with 1.16 (0.09,
2.23) for FBT, 0.81 (1.40, 3.04) for ODT,
and 0.88 (0.76, 2.55) for OTFC. Improve-
ments in pain relief were apparent within 30
minutes of treatment, with the PID being
larger for the fentanyl preparations than for
MSIR during this period (vs. placebo: MSIR
0.31 [95% CRL 2.93, 3.57]; FBT 0.73
[0.51, 1.97]; ODT 0.69 [2.08, 3.44]; and
OTFC 0.75 [1.28, 2.78]).
The PID benefit of the fentanyl products
over MSIR when compared with placebo was
maintained when the fentanyl treatments
were compared with MSIR (Table 3). When
compared with MSIR over the first 60 minutes
Table 1
Randomized Controlled Trials of Strong Oral Opioids in the Management of BTcP Identified in the Literature Search
Study Oral Opioid Study Designa Patient Number
Time Points
Analyzed (Min)
Primary Efficacy
Outcome
Secondary Efficacy
Outcomes (All in Favor
of Fentanyl
vs. Comparator)
Portenoy et al.22 FBT 100e800 mg
vs. placebo
Multicenter, double-blind,
randomized, placebo-controlled
2 phases: open-label titration
followed by 3-wk double-blind
Titration: 123
Double-blind: 77
15, 30, and 60 SPID30 (mean SE)
3.0 0.12 for FBT
vs. 1.8 0.18 for
placebo (P< 0.0001)
PR and PID at each time point,
TOTPAR, GMP assessment,
proportion of episodes $33%
or $50% improvement in PI
scores at each time point, and
use of rescue medication
Slatkin et al.23 FBT 100e800 mg
vs. placebo
Multicenter, double-blind,
randomized, placebo-controlled
2 phases: open-label titration
followed by 3-wk double-blind
Titration: 129
Double-blind: 87
5, 10, 15, 30, 45,
60, and 120
SPID60 (mean SE)
9.7 0.63 for FBT
vs. 4.9 0.50 for
placebo (P< 0.0001)
PR and PID at each time point,
TOTPAR, GMP assessment,
proportion of episodes $33%
or $50% improvement in PI
scores at each time point,
and use of rescue medication
Rauck et al.24 ODT 100e800 mg
vs. placebo
Multicenter, double-blind,
randomized, placebo-controlled
3 phases: open-label titration
followed by 2-wk double-blind
efficacy phase and an open-label
long-term safety phase
Titration: 131
Double-blind: 66
Long-term: 72
10, 15, 30, and 60 SPID30 (mean) 49.5
for ODT vs. 36.6 for
placebo (P¼ 0.0004)
SPID at 60 min, PID and PR at
each time point, GMP
assessment, responders
(%), and use of rescue
medication
Farrar et al.25 OTFC 200e1600 mg
vs. placebo
Multicenter, double-blind,
randomized, placebo-controlled
2 phases: open-label titration,
then double-blind phase
Titration: 93
Double-blind: 92
15, 30, 45, and 60 PID (P< 0.0001) and
PR scores (P< 0.0001)
better for OTFC vs.
placebo at all time
points
GMP and use of rescue
medication
Coluzzi et al.26 OTFC 200e1600 mg
vs. MSIR 15e60 mg
Multicenter, double-blind,
randomized, multiple crossover
2 phases: open-label dose-titration,
then double-blind phase
Titration: 134
Double-blind: 93
15, 30, 45, and 60 15 min PID score better
for OTFC vs. placebo
(P# 0.008)
PI, PID, PR, GMP, and use of
rescue medication
FBT¼ fentanyl buccal tablet; SPID¼ sum of pain intensity differences; SE¼ standard error; PR¼ pain reliefdmeasured on a five-point numeric scale (0¼ none; 4¼ complete); PID¼ pain intensity differ-
ence; TOTPAR¼ total pain relief; GMP¼ global medication preferencedmeasured on a five-point numeric scale (0¼ poor; 4¼ excellent); PI¼ pain intensitydmeasured on an 11-point numeric scale
(0¼ no pain; 10¼ worst pain); ODT¼ sublingual fentanyl citrate orally disintegrating tablet; OTFC¼ oral transmucosal fentanyl citrate lozenge; MSIR¼morphine sulfate immediate-release.
aIn all five studies, opioid-tolerant patients experiencing 1e4 BTcP episodes per day first entered an open-label, dose-titration phase, wherein a single, ‘‘successful’’ dose of the oral fentanyl preparation was
identified that provided effective and consistent pain relief of BTcP. This was followed by a double-blind treatment phase in which the patients were randomly assigned to prespecified treatment sequences of
the successful dose and placebo/MSIR, sufficient to treat 10 episodes of BTcP.
5
7
6
V
ol.
4
6
N
o.
4
O
ctober
2
0
1
3
Jan
dhyala
et
al.
Table 2
Source Data for the Mixed-Treatment Comparison Meta-Analysis
Study
PID for Oral Fentanyl Preparation and Control (Placebo or Morphine)
15 min 30 min 45 min 60 min
Fentanyl Control Fentanyl Control Fentanyl Control Fentanyl Control
PID Pr. PID Pr. PID Pr. PID Pr. PID Pr. PID Pr. PID Pr. PID Pr.
FBT vs. placebo
(Portenoy et al.22)a
0.90 0.77 0.60 1.13 2.30 0.42 1.40 0.54 3.30 0.30 1.90 0.38 4.00 0.24 2.30 0.27
FBT vs. placebo
(Slatkin et al.23)a
1.50 0.65 0.80 1.06 2.40 0.40 1.30 0.65 3.00 0.32 1.50 0.65 3.40 0.29 1.60 0.57
Sublingual fentanyl ODT vs.
placebo (Rauck et al.24)b
2.04 0.51 1.52 0.34 2.93 0.57 2.11 0.22 3.18 0.30 2.31 0.18 3.44 0.30 2.52 0.18
OTFC vs. MSIR
(Coluzzi et al.26)a
1.86 0.36 1.46 0.51 2.88 0.36 2.40 0.51 3.55 0.35 3.03 0.46 4.03 0.31 3.57 0.40
OTFC vs. placebo
(Farrar et al.25)a
1.62 0.81 1.02 0.81 2.41 0.52 1.51 0.59 2.88 0.45 1.91 0.40 3.19 0.40 2.13 0.32
PID¼ pain intensity difference, calculated as the difference between pretreatment (baseline) and post-treatment pain intensity scores for individ-
ual episodes of BTcP; Pr¼ precision¼ 1/variance, variances were calculated from published standard errors and 95% confidence intervals;
FBT¼ fentanyl buccal tablet; ODT¼ sublingual fentanyl citrate orally disintegrating tablet; OTFC¼ oral transmucosal fentanyl citrate lozenge.
aData from clinical study report.30e33
bData estimated from figure in article24 (15, 30, 60 min) or extrapolated as midpoint value (45 min).
Table data adapted from Jandhyala and Fullarton.27
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3.41) improvement in PID, ODT a 0.35
(3.00, 3.63) improvement and OTFC a 0.48
(1.34, 2.34) improvement. Summing the
PID calculated for MSIR against placebo with
the PID calculated for a particular fentanyl
preparation against MSIR gave a similar value
to the PID derived independently for that fen-
tanyl preparation vs. placebo (Table 3).Discussion
This study aimed to compare the efficacy of
oral morphine and three oral transmucosalTable 3
Mean Differences in PID Scores and Resultant Proba
Comparison
Min
15e30 min
Mean PID
(95% CRL)
Probability
(%)
Mean
(95%
MSIR vs. placebo 0.31 (2.93, 3.57) 56 0.56 (3
FBT vs. MSIR 0.45 (2.97, 3.91) 58 1.06 (3
Sum of PIDa 0.76 1.
FBT vs. placebo 0.73 (0.51, 1.97) 83 1.59 (0
ODT vs. MSIR 0.39 (3.94, 4.61) 56 0.32 (4
Sum of PIDa 0.70 0.
ODT vs. placebo 0.69 (2.08, 3.44) 66 0.92 (2
OTFC vs. MSIR 0.47 (2.04, 3.01) 62 0.49 (2
Sum of PIDa 0.78 1.
OTFC vs. placebo 0.75 (1.28, 2.78) 73 1.02 (1
PID¼ pain intensity difference; CRL¼ credible level; MSIR¼morphine sulfa
gual fentanyl citrate orally disintegrating tablet; OTFC¼ oral transmucosal fe
aSum of PIDs for MSIR vs. placebo plus fentanyl preparation vs. MSIR.fentanyl preparations against placebo to pro-
vide further insight into their relative merits
as treatments for BTcP. As would be expected,
all of the opioids provided superior pain relief
compared with placebo throughout the first
hour after dosing. The mixed treatment analy-
sis also suggested, however, that the oral fen-
tanyl preparations might provide a greater
level of pain relief than oral morphine.
When examined across the first hour after
dosing, the fentanyl preparations were all su-
perior to placebo: FBT 97% likelihood of su-
periority, ODT 72%, and OTFC 81%. In
comparison, there was a 61% likelihood of
oral morphine being superior to placebobilities for an Improved PID vs. Comparator
utes After Dosing
45e60 min 15e60 min
PID
CRL)
Probability
(%)
Mean PID
(95% CRL)
Probability
(%)
.22, 4.38) 60 0.44 (2.07, 2.95) 61
.11, 5.25) 66 0.75 (1.92, 3.41) 68
62 1.19
.14, 3.31) 93 1.16 (0.09, 2.23) 97
.71, 5.40) 54 0.35 (3.00, 3.63) 57
88 0.79
.58, 4.39) 67 0.81 (1.40, 3.04) 72
.14, 3.20) 62 0.48 (1.34, 2.34) 66
05 0.92
.64, 3.64) 74 0.88 (0.76, 2.55) 81
te immediate-release; FBT¼ fentanyl buccal tablet; ODT¼ sublin-
ntanyl citrate lozenge.
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terms of PID scores, the fentanyl preparations
provided around double the pain relief of
oral morphine when compared with placebo
(mean PID difference at one hour: FBT 1.16,
ODT 0.81, OTFC 0.88 vs. 0.44 for MSIR). Al-
though the fentanyl preparations appeared su-
perior to oral morphine across the whole hour
(approximately 2:1 ratio in favor of fentanyl),
the opioids were comparatively more superior
within the first 30 minutes post-dosing, albeit
with a slight advantage for the fentanyl pre-
parations (mean likelihood of superiority at
30 minutes vs. MSIR: FBT 58%, ODT 56%,
OTFC 62%). This is of potential importance
because most BTcP episodes occur within 30
minutes. It also should be noted that there
was considerable overlap in the CRLs for the
resultant PID scores for each treatment. How-
ever, despite this overlap in CRLs, review of
the PID scores generated in the analysis re-
vealed that summing the PID for MSIR vs. pla-
cebo with the PID for a fentanyl preparation
gave a remarkably consistent result to that
from the independent placebo analysis. This
lends further credibility to the results when
compared with that of MSIR. Our results are
consistent with a previous mixed-treatment
comparison of intranasal fentanyl and other
opioids for BTcP, which showed a greater
pain reduction for the fentanyl preparation
over oral morphine.34
The small number of studies available, par-
ticularly with regard to comparison of the fen-
tanyl preparations with oral morphine/MSIR,
is a limitation of this mixed-treatment compar-
ison. Obtaining the raw numbers for the PID
scores in the Rauck et al.24 study (ODT vs. pla-
cebo) also would have been useful to improve
the precision of the outputs, although they
would not be expected to change the results
materially. Although indirect comparisons can
potentially be biased by differences in study de-
sign and sample populations, including vari-
ability in inclusion and exclusion criteria and
definitions of effective dose, the randomized,
controlled trials used in this analysis were per-
formed according to methodologically compa-
rable protocols. Visual inspection of the data
also indicated that there was no significant het-
erogeneity between the placebo-controlled
studies that would preclude their combination
in a mixed-treatment comparison. However,the possibility of systematic differences be-
tween data sources that were not detected by
heterogeneity analysis cannot be ruled out. Al-
though a well-documented and recognized
technique for meta-analysis, it also should be
recognized that Bayesian sampling was carried
out by a computerized process that could in-
fuse some (albeit small) level of machine bias,
despite the use of 10,000 sample points in every
analysis.
The results of the mixed-treatment compari-
son provide additional information on the
comparative efficacy of the oral fentanyl prepa-
rations and oral morphine in the treatment of
BTcP. Another key consideration when decid-
ing on the most effective treatment for a pa-
tient is the balance between efficacy and
tolerability. It could potentially be argued that
the prolonged duration of action of oral mor-
phine in comparison with the fentanyl prepara-
tions might result in an extended opportunity
for adverse events.4,19 At present, however,
most available data come from placebo-
controlled studies, as described herein, and fo-
cus on the efficacy of the preparations, and not
on tolerability, with all products reported to
cause ‘‘typical’’ opioid adverse events, such as
nausea, vomiting, dizziness, constipation, and
somnolence.22e26 The only comparative data
are from the Coluzzi et al.26 study, which, be-
cause of the study design, had patients receiv-
ing concomitant ATC medication as well as
OTFC and MSIR during the double-blind
phase, making it difficult to attribute any ad-
verse events to a specific product. Indirect evi-
dence from patient preference surveys, which
take into account the mode of administration
and efficacy as well as tolerability, indicate
that the fentanyl preparations might have
some advantages over oral morphine beyond
efficacy. For example, in a longer-term follow-
up study of two double-blind studies,22,23 88%
of the patients were reported to prefer FBT
over their previous BTcP medication.35 Further
work, however, is needed to formally assess the
comparative tolerability of the various prepara-
tions, to help put the results of this efficacy
analysis into the wider clinical context.
This study suggests that although oral mor-
phine remains an adequate treatment option
for BTcP, there might be clinical advantages
to using one of the oral transmucosal fentanyl
preparations in some patients.
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